ReviewNature reviews. Nephrology2012
An update on peritoneal dialysis solutions.
Review in Nature reviews. Nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Therapeutic potential of amino acid-based peritoneal dialysis solutions: a systematic review.BMC nephrology · 2026Pooled it
- Functional and Transcriptomic Characterization of Peritoneal Immune-Modulation by Addition of Alanyl-Glutamine to Dialysis Fluid.Scientific reports · 2017Trial
- Addition of Alanyl-Glutamine to Dialysis Fluid Restores Peritoneal Cellular Stress Responses - A First-In-Man Trial.PloS one · 2016Trial
- Benefits of a continuous ambulatory peritoneal dialysis (CAPD) technique with one icodextrin-containing and two biocompatible glucose-containing dialysates for preservation of residual renal function and biocompatibility in incident CAPD patients.Journal of Korean medical science · 2014Trial
- Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisTrial
- Effect of icodextrin on heart rate variability in diabetic patients on peritoneal dialysis.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisTrial
- Acute peritoneal dialysis adequacy among children at a national referral hospital in Kenya: a cross-sectional study in a resource-limited setting.BMC nephrology · 2026Article
- The effect of icodextrin on peritoneal dialysis patients with congestive heart failure: a time-varying exposure design and target trial emulation approach.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- Clinical rationale behind glucose-sparing strategies in peritoneal dialysis: a narrative review.BMC nephrology · 2026Review
- Effects of different peritoneal dialysis solutions on serum lipid levels and lipid profile in end-stage chronic kidney disease patients undergoing peritoneal dialysis.BMC nephrology · 2025Article
- Improvement of lactic acidosis in pyruvate dehydrogenase complex deficiency using custom-made amino acid-based dialysate for peritoneal dialysis.Pediatric nephrology (Berlin, Germany) · 2025Article
- Glycemic Control in Patients with Diabetes on Peritoneal Dialysis: From Glucose Sparing Approach to Glucose Monitoring.Life (Basel, Switzerland) · 2025Review
- Aquaporin-1 and Osmosis: From Physiology to Precision in Peritoneal Dialysis.Journal of the American Society of Nephrology : JASN · 2024Review
- Baxter Physioneal, Extraneal, Nutrineal (PEN) and Dianeal solution bags can be accidentally connected to Fresenius peritoneal dialysis catheter extensions in a non-sterile manner.Clinical kidney journal · 2024Article
- Peritoneal fibrosis: from pathophysiological mechanism to medicine.Frontiers in physiology · 2024Review
- Article
- Impact of initial dialysis modality on the survival of patients with ESRD: a propensity-score-matched study.BMC nephrology · 2023Article
- Comparison of the risks of renal cell carcinoma or urothelial cancer between hemodialysis and peritoneal dialysis patients.International urology and nephrology · 2023Article
- Care of the pediatric patient on chronic peritoneal dialysis.Pediatric nephrology (Berlin, Germany) · 2022Article
- A Review on Major Pathways Leading to Peritoneal Fibrosis in Patients Receiving Continuous Peritoneal Dialysis.Cureus · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal dialysis (PD) has achieved its current position as the most commonly used home-based dialysis therapy--and with patient survival equal to that seen with hemodialysis--despite the use of glucose-based dialysis solutions with high concentrations of glucose, glucose degradation products and lactate, high osmolality, and low pH, features that are harmful both for the peritoneum and the patient. Newer PD solutions with alternative buffers, a higher pH and fewer glucose degradation products, or ones that contain icodextrin or amino acids as osmotic agents, have been introduced in many countries and have been shown to improve peritoneal membrane health and viability. Icodextrin solution enhances fluid and sodium removal, and the once-daily use of icodextrin and/or amino acid solutions can lessen the harmful effects caused by the exposure of the peritoneal membrane to glucose. However, whether the newer PD solutions improve patient survival over the older solutions is not clear. Use of PD therapy, with or without the newer PD solutions, is associated with an improvement in patient survival that is equivalent to that obtained with hemodialysis. Therefore, the conventional glucose-based solutions--despite their known negative features--continue to have a well-established role in PD therapy, particularly in the many countries where the newer PD solutions are not easily available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.